Background
Phase 2, open-label, randomized controlled trial (EVAN). N=102 patients with completely resected stage IIIA NSCLC with EGFR activating mutations (exon 19 del or L858R), confirmed by PCR, R0 resection, ECOG PS 0–1. Chinese single-center study addressing the high-risk stage IIIA EGFR-mutated subset.
Interventions and follow up
Arm A: Erlotinib 150 mg PO daily × 2 years (N=51)
Arm B: Vinorelbine 25 mg/m² IV days 1 and 8 q3wk + cisplatin 75 mg/m² IV day 1 × 4 cycles (N=51)
Primary endpoint: 2-year event-free survival (EFS)
mFollow up: 51 months
Arm B: Vinorelbine 25 mg/m² IV days 1 and 8 q3wk + cisplatin 75 mg/m² IV day 1 × 4 cycles (N=51)
Primary endpoint: 2-year event-free survival (EFS)
mFollow up: 51 months
Results
2-yr EFS: 81.4% (erlotinib) vs 44.6% (chemo), HR 0.27, 95% CI 0.14–0.53, P<.001
OS (updated, exploratory): mOS 84.2 vs 61.1 mo, HR 0.32, P<.001
OS (updated, exploratory): mOS 84.2 vs 61.1 mo, HR 0.32, P<.001
Adverse events
Overall Grade ≥3: 12.9% (erlotinib) vs 45.1% (chemo)
Erlotinib Grade ≥3: rash 2.0%, diarrhea 2.0%
Chemotherapy Grade ≥3: neutropenia 29.4%, nausea/vomiting 17.6%
Other: no treatment-related deaths
Erlotinib Grade ≥3: rash 2.0%, diarrhea 2.0%
Chemotherapy Grade ≥3: neutropenia 29.4%, nausea/vomiting 17.6%
Other: no treatment-related deaths
Conclusions
Adjuvant erlotinib demonstrated markedly improved 2-year EFS (HR 0.27) and exploratory OS benefit vs platinum-doublet chemotherapy in resected stage IIIA EGFR-mutated NSCLC, with substantially lower toxicity.
Key Limitations
Phase 2 trial, single-center, N=102 only — insufficient for regulatory decision-making. OS benefit was not a pre-specified primary endpoint and is exploratory. Erlotinib (1st-gen TKI) provides no T790M coverage. Osimertinib (ADAURA) has now proven OS benefit with 3rd-generation TKI and should be preferred. Chinese single-center limits generalizability. Stage IIIA definition varies across staging editions.
Clinical Context
EVAN reinforced the DFS proof-of-concept from ADJUVANT/CTONG1104 for the specific high-risk stage IIIA subgroup. The exploratory OS HR 0.32 is striking but unconfirmed in a phase III trial. Per ASCO and ESMO, ADAURA (osimertinib) is now the evidence-based standard adjuvant targeted therapy in EGFR+ NSCLC. EVAN is primarily of historical interest. ESMO-MCBS: phase 2 (not formally scored).